B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
B7-H3 and B7x are recently discovered members of the B7-CD28 family thought to dampen peripheral immune responses via negative costimulation. We evaluated their potential expression in human prostate cancer using a large cohort of patients with 7 years of follow-up. We identified 823 patients with tissue available treated with radical prostatectomy between 1985 and 2003. Immunohistochemistry was performed on tissue microarray sections using anti-B7-H3 and -B7x. The percentage and intensity of immunoreactivity by tumor cells were blindly evaluated by two urological pathologists, and outcome analyses were conducted. Both B7-H3 and B7x were highly expressed; 93% and 99% of tumors had aberrant expression, respectively. The median percentage of tumor cells staining positive was 80% for each molecule. Strong intensity for B7-H3 and B7x was noted in 212 (26%) and 120 (15%) patients, respectively. Patients with strong intensity for B7-H3 and B7x were significantly more likely to have disease spread at time of surgery ( P < 0.001 and P = 0.005, respectively). Additionally, patients with strong intensity for B7-H3 and B7x were at significantly increased risk of clinical cancer recurrence ( P < 0.001 and P = 0.005) and cancer-specific death ( P = 0.004 and P = 0.04, respectively). To our knowledge, we present the largest investigation of B7 family molecules in a human malignancy and a previously undescribed evaluation of B7x in prostate cancer. B7-H3 and B7x are abundantly expressed in prostate cancer and associated with disease spread and poor outcome. Given the proposed immune-inhibitory mechanisms of B7-H3 and B7x, these molecules represent attractive targets for therapeutic manipulation in prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As a result, overexpression of B7H3 is associated with disease spread, including increased extracapsular extension and seminal vesicle invasion, as well as worse outcomes, including higher risk of metastatic recurrence or subsequent development of CRPC88.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citationDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Self-citationHamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
Townsend, S. E., & Allison, J. P. (1993) · Science · doi:10.1126/science.7678351 · Cited by 1,136
Self-citationB7-H3: A costimulatory molecule for T cell activation and IFN-γ production
Chapoval, A. I., Ni, J., Lau, J. S., Wilcox, R. A., Flies, D. B., Liu, D., Dong, H., Sica, G. L., Zhu, G., Tamada, K., et al. (2001) · Nature Immunology · doi:10.1038/85339 · Cited by 1,015
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Self-citation
Cited by
Items 301–400 of 420
Liu, W., Jiang, Q.-Y., Qi, Z., Zhang, F., Tang, W., Wang, H., & Dong, L. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s469529 · Cited by 9
Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors
Wilczyński, J. R., & Nowak, M. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1300-4_8 · Cited by 9
Isolation and Validation of Anti-B7-H4 scFvs from an Ovarian Cancer scFv Yeast-Display Library
Laniti, D. D., & Scholler, N. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2748-7_2 · Cited by 9
Aberrant expression of B7-H4 may contribute to the development of hepatocellular carcinoma
Yuan, L., Dong, L., Yu, G., Fan, W., Zhang, L., Wang, P., Hu, X., & Zhao, M. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5887 · Cited by 9
Huang, Y., Huang, Z., Cai, H., Zhuge, L., Wang, S., Yan, D., Zhang, X., An, C., Niu, L., & Li, Z. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24811 · Cited by 9
Genome-wide identification and evolutionary analysis of B7-H3
Duan, H., & Huang, M. (2012) · International Journal of Data Mining and Bioinformatics · doi:10.1504/ijdmb.2012.049247 · Cited by 9
Fang, T., Xia, Y., Li, Y., Xu, S., Li, H., Wang, S., Huang, P., Qian, Y., Jin, P., Jin, N. Y., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2516294 · Cited by 8
“16 17–21 The human B7-H3 protein exists either as a transmembrane or soluble isoform.”
Bam, R., Natarajan, A., Tabesh, F., Paulmurugan, R., & Dahl, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109048 · Cited by 8
“It has been reported that several cancer types express B7-H3 at higher level [20,27] which include prostate cancer [28,29], renal cell carcinoma [30], ovarian cancer [31], glioblastoma [32], osteosarcoma [33], pancreatic cancer [34], neuroblastoma [35], diffuse intrinsic pontine glioma, and mesothelioma [36,37].”
BackgroundDynamics of prostate cancer stem cells with diffusion and organism response
Quinn, T. J., & Sinkala, Z. (2008) · Biosystems · doi:10.1016/j.biosystems.2008.11.010 · Cited by 8
Leung, J., St-Onge, P., Stagg, J., & Suh, W. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1950-2 · Cited by 8
B7-H4’s Role “Beyond the Tumor”
Yu, N., Li, X., Zheng, S., & Li, X.-P. (2013) · Inflammation · doi:10.1007/s10753-013-9624-0 · Cited by 8
Chen, X., Wang, W., Man, H., Li, P., & Shan, B. (2017) · Oncology Letters · doi:10.3892/ol.2017.5688 · Cited by 8
Birappa, G., Perumalsamy, H., Hong, S.-H., Gowda, D. A. A., Chandrasekaran, A. P., Karapurkar, J. K., Rajkumar, S., Balusamy, S. R., Jayachandran, A., Baek, K., et al. (2025) · Theranostics · doi:10.7150/thno.117900 · Cited by 7
Oroujeni, M., Carlqvist, M., Ryer, E., Orlova, A., Максимилианович, Т. В., & Frejd, F. Y. (2024) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-024-00261-3 · Cited by 7
“…be noted that B7-H3 is overexpressed on differentiated malignant and cancer-initiating cells in many different cancer types (Roth et al. 2007; Zang et al. 2007, 2010; Crispen et al. 2008; Boorjian et al. 2008; Lemke et al. 2012; Ingebrigtsen et al. 2014; Sun et al. 2014; Bachawal et al.…”
BackgroundDawidowicz, M., Kula, A., Mielcarska, S., Świętochowska, E., & Waniczek, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25095045 · Cited by 7
“They consisted of the following cancer types: OS—osteosarcoma [27], Pca—prostate cancer [28,29], CvC—cervical cancer [30,31], CCA—cholangiocarcinoma [13,32], PDAC—pancreatic ductal adenocarcinoma [33–36], UCC—urothelial cell carcinoma [36], HNSCC—head and neck squamous cell carcinoma [37,38],…”
BackgroundXiao, M., Pang, C., Xiang, S., Zhao, Y., Wu, X., Li, M., Du, F., Chen, Y., Wang, F., Wen, Q., et al. (2023) · Scientific Reports · doi:10.1038/s41598-022-26776-w · Cited by 7
Immune Profiling of Meningiomas
Wang, J. Z., Nassiri, F., Bi, L., & Zadeh, G. M. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-29750-2_14 · Cited by 7
Expression of B7–H4 in endometrial cancer and its impact on patients’ prognosis
Gorzelnik, K., Wasążnik-Jędras, A., Wicherek, Ł., & Szubert, S. (2023) · Ginekologia Polska · doi:10.5603/gpl.96605 · Cited by 7
A Pan-Cancer Analysis of the Oncogenic Role of CD276 in Human Tumors
Liu, L., Yao, Z., Liu, Y., Li, Y., Ding, Y., Hu, J., Liu, Z., Shi, P., Chen, K., Liu, Z., et al. (2024) · Genes · doi:10.3390/genes15121527 · Cited by 7
Kang, N., Xue, H., Wong, N. K. Y., Lin, Y., Classen, A., Wu, R., Oo, H. Z., Dong, X., Trinh, A. M., Lin, D., et al. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0958 · Cited by 7
Johnson, A. A., & Shokhirev, M. N. (2021) · Rejuvenation Research · doi:10.1089/rej.2021.0012 · Cited by 7
Zhou, B., Lu, Y., Zhao, Z., Shi, T., Wu, H., Chen, W., Zhang, L., & Zhang, X. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02567-1 · Cited by 7
Prognostic value of soluble H7-B4 in pleural effusion associated with lung cancer
Xu, C., Cao, L., Zhang, X., Yan, J., & Yu, L. (2015) · Tumor Biology · doi:10.1007/s13277-015-3079-x · Cited by 7
“cancer, and has been shown to be a prognostic marker in some cancers [12–20].”
BackgroundCloning and Characterization of Porcine 4Ig-B7-H3: A Potent Inhibitor of Porcine T-Cell Activation
Chen, W., Hou, Z., Li, C., Xiong, S., & Liu, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021341 · Cited by 7
Considerations for Combined Immune Checkpoint Modulation and Radiation Treatment
Almo, S. C., & Guha, C. (2014) · Radiation Research · doi:10.1667/rr13667.1 · Cited by 7
Spatiotemporal Changes in Checkpoint Molecule Expression
Li, W., Qie, J., Zhang, Y., & Chang, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_8 · Cited by 7
Preparation and Characterization of Monoclonal Antibody Against Human B7-H4 Molecule
Zhang, N., Fang, P., & Gu, Z. (2014) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2013.0082 · Cited by 7
Liu, Q., Huang, H., Zhang, S., Liu, F., & Lou, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1480447 · Cited by 6
Funeh, C. N., Meeus, F., Winnendael, N. V., Groof, T. W. M. D., D’Huyvetter, M., & Devoogdt, N. (2025) · Pharmaceuticals · doi:10.3390/ph18101477 · Cited by 5
B7–H4 ImmunoPET Imaging Tracks Tumor-Associated Macrophage Changes in Prostate Cancer
Kumar, M., Singh, S. B., Vasyliv, I., Habte, F. G., Kalita, M., Alam, I. S., Koladiya, A., Dai, S., James, M. L., Rao, J., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00637 · Cited by 5
Soares, J., Ferreira, D., Miranda, A., Gonçalves, M., Relvas‐Santos, M., Brandão, A., Paulo, P., Cotton, S., Freitas, R., Magalhães, M., et al. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02672-y · Cited by 5
sB7-H3 as a prognostic biomarker in osteosarcoma: insights into clinical outcomes
Zhao, Y., Sun, K., Yu, Y., Xu, J., Wang, Y., Yang, C., Ma, H., Zhou, Y., Ren, T., Tang, X., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-40855-2 · Cited by 5
Framework of Intrinsic Immune Landscape of Dormant Prostate Cancer
Wong, N. K. Y., Dong, X., Lin, Y., Xue, H., Wu, R., Lin, D., Collins, C. C., & Wang, Y. Z. (2022) · Cells · doi:10.3390/cells11091550 · Cited by 5
“Consistent with its potential role in immune evasion and, thereby, promoting tumor progression, B7-H3 expression has been shown to correlate with tumor aggressiveness [67,68] and poor clinical outcomes [69,70] in various cancers.”
BackgroundRaja, D., Singh, A. P., Kurra, S., Nayak, B., Kaushal, S., Sharma, A., & Singh, P. (2024) · Medical Oncology · doi:10.1007/s12032-024-02299-4 · Cited by 4
“A study by Zang et.al. has reported similar observation showcasing positive association of B7-H4 with clinical parameters in prostate cancer [34].”
A Novel Monoclonal Antibody Against Mouse B7-H3 Developed in Rats
Yan, R., Yang, S. F., Sun, J., Chen, X., Zhang, G., Feng, P., & Zhang, X. (2012) · Hybridoma · doi:10.1089/hyb.2012.0008 · Cited by 4
Immune Co-signaling to Treat Cancer
Callahan, M. K., Wolchok, J. D., Allison, J. P., & Sharma, P. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_8 · Cited by 4
Self-citationFunctional Analysis of B7-H3 in Colonic Carcinoma Cells
Lu, P., Liu, R., Ma, E.-M., Yang, T., & Liu, J. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.8.3899 · Cited by 4
“high-grade prostatic intraepithelial neoplastic, and four prostate cancer cell lines and expressed by benign prostatic epithelia (Roth et al., 2007; Zang et al., 2007; Yuan et al., 2011).”
BackgroundT cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer
Greiner, S. M., Mauermann, J., Lutz, M. S., Hagelstein, I., Hartkopf, A. D., Zekri, L., Jung, G., Salih, H. R., & Märklin, M. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06825-4 · Cited by 3
“In addition, high CD276 expression is associated with poorer prognosis in various cancer entities [19–22], e.g. higher tumor grade, shorter OS, and a lower presence of tumor-infiltrating lymphocytes [10, 11].”
Meenakshi, S., Maharana, K. C., Nama, L., Vadla, U. K., Dhingra, S., Ravichandiran, V., Murti, K., & Kumar, N. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230809110444 · Cited by 3
The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma
Tang, G., Liu, J., Qi, L., & Li, Y. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15504 · Cited by 3
Fard, A. K. L., Haake, A. F. H., Jovanović, V., Andreotti, S., Hummel, M., Hempel, B.-F., & Gruber, A. D. (2024) · PeerJ · doi:10.7717/peerj.18444 · Cited by 3
Overview of the Soluble and Membrane-bound Tumor Factors Limiting NKmediated Immune Surveillance
Bottino, C., Chiesa, M. D., Dondero, A., Bellora, F., Casu, B., Moretta, A., & Castriconi, R. (2017) · Immunotherapy Open Access · doi:10.4172/2471-9552.1000136 · Cited by 3
Liu, Y., Wu, X., Li, X., Kvalheim, G., Axcrona, U., Axcrona, K., & Suo, Z. (2013) · Ultrastructural Pathology · doi:10.3109/01913123.2013.770112 · Cited by 3
Fc-optimized CD276 antibody enhances NK cell activation against non-small cell lung cancer
Stefanczyk, S. A., Kaiser, X., Hagelstein, I., Holzmayer, S. J., Zekri, L., Jung, S., & Märklin, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1624751 · Cited by 2
Prognostic and therapeutic roles of B7-H3 and B7-H4 in prostate cancer
Hu, Y., Yang, W., Guo, S., & Huang, D. (2026) · Discover Oncology · doi:10.1007/s12672-026-04926-0 · Cited by 2
“High B7-H3 expression is consistently associated with a range of adverse clinical outcomes, including high Gleason score, advanced pathological stage, extraprostatic extension, seminal vesicle invasion, lymph node metastasis, biochemical recurrence (BCR), and PCa-specific mortality [13, 14, 19, 22].”
InfluentialB7-H3 (CD276): an actionable therapeutic target and prognostic biomarker across human malignancies
Smith, D., Tyagi, A., & Battula, V. L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1857767 · Cited by 2
Emerging antibody-drug conjugates in metastatic castration-resistant prostate cancer
Nguyen, C. B., & Reichert, Z. R. (2026) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2026.06.022 · Cited by 2
Development of Ultrasound Microbubbles and Phase Shift Microbubbles in Theranostics
Meuillet, E. J., & Unger, E. C. (2026) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70068 · Cited by 2
“B7-H3 (CD-276), a transmembrane glycoprotein, is expressed in DCIS but not in fibroadenoma (Cimino-Mathews et al. 2015; Kim et al. 2020; Loos et al. 2010; Zang et al. 2007).”
The Role of T-Cell Costimulatory Pathways in Regulation of Autoimmune Diabetes
Lee, I. (2011) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.s2-002 · Cited by 2
Starzyńska, A., Sejda, A., Adamski, Ł. J., Adamska, P., Pęksa, R., Sakowicz‐Burkiewicz, M., Wychowański, P., & Jereczek‐Fossa, B. A. (2020) · Advances in Dermatology and Allergology · doi:10.5114/ada.2020.98523 · Cited by 2
Interleukin-1 Superfamily and Cancer
Yuzhalin, A. E., & Kutikhin, A. G. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801121-8.00002-6 · Cited by 2
RGS4, CD95L and B7H3: Targeting evasive resistance and the immune privilege of glioblastoma
Pfenning, P. (2011) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00011962 · Cited by 2
B7-H3 and digestive system cancers
Zhou, L., Jiang, Z., Gu, J., Gu, W., & Han, S. (2021) · European Journal of Inflammation · doi:10.1177/20587392211000581 · Cited by 1
Runtunuwu, S. V. B. E., Tallei, T. E., Kim, H. J., Park, M. N., Çelik, İ., Kirilmaz, B., Turalaki, G. L. A., Fatimawali, F., Tendean, L. E. N., Kaseke, M. M., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1716345 · Cited by 1
“To simulate a clinically relevant vaccination strategy, four vaccine doses were administered at 2-week intervals (78), corresponding to time steps 1, 43, 85, and 127, where each time step represents 8 h (79).”
Zhai, C., Ye, J., Li, X., Liu, J., Zhou, X., Wang, Z., Zhang, X., Zeng, W., Luo, H., Chen, L., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1751400 · Cited by 1
Makovec, A., Gustafson, A. P., Gandhi, N. S., Rampalli, S., Arafa, A. T., Elliott, A., Smith, N., Felices, M., Kennedy, P. R., Shenderov, E., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-0322 · Cited by 1
B7-H4 in Cancer Immune Evasion and Immunotherapy
Xiao, R., Yu, J., Yan, Y., Kryczek, I., & Zou, W. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2442 · Cited by 1
Xu, Y., Li, F., Cui, Z., Xie, H., Xu, L., Lin, Y., Li, T., Li, N., Cao, D., He, W., et al. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-26-0395 · Cited by 1
Leo, J., Chen, F., Wei, S., Liang, X., Meng, C., Gu, Q., Albittar, Y., Fan, Z., Zhang, J., Gan, B., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03921-7 · Cited by 1
Wang, J., & Chen, L. (2017) · Springer eBooks · doi:10.1007/978-1-4419-0717-2_48 · Cited by 1
Development of novel immune interventions for genito-urinary cancers
Agarwal, N., & Vogelzang, N. J. (2013) · CRC Press eBooks · doi:10.3109/9781841848303-4 · Cited by 1
Kulemzin, S. V., Gorchakov, A. A., & Taranin, A. V. (2019) · Cellular Therapy and Transplantation · doi:10.18620/ctt-1866-8836-2019-8-4-19-28 · Cited by 1
Кушлинский, Н. Е., Kovaleva, O. V., Alferov, A. A., Kuzmin, Y. B., Сушенцов, Е. А., & Stilidi, I. S. (2021) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2021-49-013 · Cited by 1
Duijvesz, D., & Jenster, G. W. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2864-9_35 · Cited by 1
Recent Advances in Nanomaterial-Based Immunotherapy for Prostate Cancer: A Comprehensive Review
Kumar, A., Lunawat, A. K., Narang, R. K., & Kumar, M. (2024) · Current Nanomaterials · doi:10.2174/0124054615308368240521075603 · Cited by 1
Куркин, Д. В., Андреевич, О. Н., Makarova, A. R., GALKINA, D. A., Bakulin, D. A., Shatalova, O. V., Strygin, A. V., Petrov, V. I., Marincheva, O. V., Gorbunova, Y. V., et al. (2025) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2024-12-6-431-470 · Cited by 1
NLRX1 Drives Prostate Cancer Progression Through Activation of AKT and ERK Signaling Pathways
Rathore, V., Cheng, C.-Y., Huang, D.-Y., Chen, S.-P., Wu, L. H., Maharana, J., Chang, C., & Lin, W. (2026) · International Journal of Biological Sciences · doi:10.7150/ijbs.126054 · Cited by 1
Du, H., Hirabayashi, K., Ahn, S., Kren, N. P., Montgomery, S. A., Wang, X., Tiruthani, K., Mirlekar, R., Michaud, D. E., Greene, K. G., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3280238 · Cited by 1
Zheng, M., Zhao, S., Fu, F., Wang, Y., Zhang, K., Liu, Q., Mu, H., Li, S., Zhang, X., & Miao, L. (2023) · Research Square · doi:10.21203/rs.3.rs-2871179/v1 · Cited by 1
Statins inhibit onco-dimerization of the 4Ig isoform of B7-H3Preprint
Sutton, M. N., Glazer, S. E., Zaki, A. A., Napoli, A. D., Yang, P., Bhosale, P., Liu, J., Gammon, S. T., & Piwnica-Worms, D. R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.18.628944 · Cited by 1
Regulation of anti-tumor T cell immunity by the B7 family member B7-H4
Leung, J. (2016) · doi:10.82308/39186 · Cited by 1
Immunogenicity of pluripotent stem cells and their differentiation products
Monecke, S. (2013) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-3881 · Cited by 1
ON IMMUNOTHERAPY AGAINST PROSTATE CANCER
Lundberg, K. (2010) · Figshare
Tim-3/Gal-9 and B7-H3 act as negative regulators of graft versus host disease
Veenstra, R. G. (2013) · University of Minnesota Digital Conservancy (University of Minnesota)
Wastiaux, H. (2012) · The Open Immunology Journal · doi:10.2174/1874226201205010001
B7-H4 expression and increased death risk of cancer patients: A meta-analysis
Jiang, J., Wu, C., Zheng, X., Zhao, Y., Xu, B., Lu, B., & Shen, Y. (2011) · Clinical Oncology and Cancer Research · doi:10.1007/s11805-011-0586-4
Expression of Costimulatory Molecules B7-H4 in PBC Patients
Zhao, C., Zhao, Y., Li, Y. Z., Hu, C. J., & Liu, D. H. (2013) · Advanced materials research · doi:10.4028/www.scientific.net/amr.850-851.1216
Evolutionary Of Prostate Cancer Stem Cells In Prostate Duct
Sinkala, Z. (2010) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.1328565
Genetical, structural and functional characterization of the human BTNL gene cluster
Aigner, J. (2013) · Repositori digital de la UPF (Universitat Pompeu Fabra)
Wang, J., & Chen, L. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6613-0_48-6
Extratumoral effects of highly aggressive prostate cancer
Strömvall, K. (2017) · DiVA (Digitala Vetenskapliga Arkivet)
『西鶴置土産』における連句的手法 -付合語および視点・人称を視座として-
大野, 鵠. (1999) · 国文学会誌
Sharma, P., Subudhi, S. K., Peggs, K. S., Goswami, S., Gao, J., Quezada, S. A., & Allison, J. P. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm068
Self-citation(2008) · The Journal of Urology · doi:10.1016/j.juro.2007.11.161
Development of novel immune interventions for genito-urinary cancers
Agarwal, N., & Vogelzang, N. J. (2011) · Informa Healthcare eBooks · doi:10.3109/9781841848303.003
Ο ρόλος των μεμβρανικών γλυκοπρωτεϊνών στον καρκίνο των ωοθηκών
Ντάνγκαη, Ν. (2013) · doi:10.12681/eadd/28401
El‐Deiry, W. S., & Zhou, L. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735453137.793558758
Interleukin-10 Superfamily and Cancer
Yuzhalin, A. E., & Kutikhin, A. G. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801121-8.00006-3
Raja, D., Singh, A. P., Kurra, S., Nayak, B., Kaushal, S., Sharma, A., & Singh, P. (2022) · Research Square · doi:10.21203/rs.3.rs-2186489/v1
In vivo imaging of T-cell coregulator B7-H4 reveals protumor macrophage status in prostate cancerPreprint
Kumar, M., Singh, S. B., Vasyliv, I., Habte, F. G., Kalita, M., Alam, I. S., Dai, S., James, M. L., Rao, J., Bézière, N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.28.615608
The B7-H3 Protein and its role in Breast Cancer Treatment Response
Pedersen, C. (2012) · NORA - Norwegian Open Research Archives
Zhou, B., Lu, Y., Zhao, Z., Shi, T., Wu, H., Chen, W., Zhang, L., & Zhang, X. (2022) · Figshare · doi:10.6084/m9.figshare.19582158
Zhou, B., Lu, Y., Zhao, Z., Shi, T., Wu, H., Chen, W., Zhang, L., & Zhang, X. (2022) · Figshare · doi:10.6084/m9.figshare.19582176
Zhou, B., Lu, Y., Zhao, Z., Shi, T., Wu, H., Chen, W., Zhang, L., & Zhang, X. (2022) · Figshare · doi:10.6084/m9.figshare.19582173
Rodrigues, J. C. (2008) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/1953
Zhou, B., Lu, Y., Zhao, Z., Shi, T., Wu, H., Chen, W., Zhang, L., & Zhang, X. (2022) · Figshare · doi:10.6084/m9.figshare.19582164
Zhou, B., Lu, Y., Zhao, Z., Shi, T., Wu, H., Chen, W., Zhang, L., & Zhang, X. (2022) · Figshare · doi:10.6084/m9.figshare.19582170
Zhou, B., Lu, Y., Zhao, Z., Shi, T., Wu, H., Chen, W., Zhang, L., & Zhang, X. (2022) · Figshare · doi:10.6084/m9.figshare.19582167
Zhou, B., Lu, Y., Zhao, Z., Shi, T., Wu, H., Chen, W., Zhang, L., & Zhang, X. (2022) · Figshare · doi:10.6084/m9.figshare.19582161
Metadata
- Authors
- Zang, X., Thompson, R. H., Al-Ahmadie, H. A., Serio, A. M., Reuter, V. E., Eastham, J. A., Scardino, P. T., Sharma, P., & Allison, J. P.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of Chicago Medical Center (US)
- Pathology, and
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Allison, James P.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2007-12-04
- Volume
- 104
- Issue
- 49
- Pages
- 19458-19463
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2148311
- OpenAlex
- W2164079212
- Cited by
- 401
- References
- 42
- Citations by year
- 2026: 20 · 2025: 15 · 2024: 20 · 2023: 23 · 2022: 27 · 2021: 28 · 2020: 22 · 2019: 19 · 2018: 21 · 2017: 26 · 2016: 31 · 2015: 15 · 2014: 22 · 2013: 25 · 2012: 27
- FWCI
- 11.81
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research Institute
- Prostate Cancer Foundation
- National Cancer Institute (T32CA082088)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- B7-H3, prostate cancer, B7/CD28 family, tumor immune evasion, tumor recurrence, cancer-specific mortality, lymph node metastasis, prognostic factors, immunotherapy targets, radical prostatectomy
- MeSH terms
- Humans, Immunohistochemistry, Male, Prognosis, Prostatic Neoplasms, Receptors, Immunologic, Antigens, CD, Survival Analysis, B7-1 Antigen, Disease Progression, B7 Antigens, V-Set Domain-Containing T-Cell Activation Inhibitor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.